Condition: Breast Cancer · Colon Cancer · Lung Cancer · Sponsor: University of Arizona
The use of immune checkpoint inhibitors (ICIs), alone or in combination with other cancer treatments is increasing dramatically with immune-related adverse events (irAEs) common (90%) during ICI treatment. Most irAEs are symptomatic and symptom self-management with timely reporting of moderate or severe symptoms to health care providers (HCPs) may reduce irAE severity by early recognition and management, resulting in fewer treatment interruptions and unscheduled health services.
This description comes directly from the study's public registry record.
Molly Hadeed · 520-626-0583 · mcbarry@arizona.edu
Always discuss trial participation with your own doctor first.
| Valleywise Health Medical Center | Phoenix, Arizona, United States | Active Not Recruiting |
| University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05715255